HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells

INTRODUCTION: Although the mechanistic target of rapamycin (mTOR) might be a promising molecular target to treat advanced bladder cancer, resistance develops under chronic exposure to an mTOR inhibitor (everolimus, temsirolimus). Based on earlier studies, we proposed that histone deacetylase (HDAC)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Juengel, Eva, Najafi, Ramin, Rutz, Jochen, Maxeiner, Sebastian, Makarevic, Jasmina, Roos, Frederik, Tsaur, Igor, Haferkamp, Axel, Blaheta, Roman A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746361/
https://ncbi.nlm.nih.gov/pubmed/29299126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22454
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak